Therefore, the efficacy of genotype-guided therapy in optimizing P2Y12 inhibitor selection for chronic kidney disease patients undergoing PCI was limited based on the findings of this analysis.[31] The PERGENE study aimed to personalize ACE inhibitor therapy in stable CAD based on clinical and pharmacogenetic factors. Here, ACE is linked to chronic kidney disease.